Praxis Precision Medicines Inc
PRAX
Market Cap$875.87M
Close$
$13.51
67.9% downside
Current Fair Value
67.9% downsideOvervalued by 67.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $875.87 Million |
|---|---|
| Enterprise Value | $711.37 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-10.21 |
| Beta | 2.62 |
| Outstanding Shares | 21,055,834 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.26 |
|---|---|
| PEG | -5.66 |
| Price to Sales | - |
| Price to Book Ratio | 2.1 |
| Enterprise Value to Revenue | 87.59 |
| Enterprise Value to EBIT | -3.05 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Praxis Precision Medicines Inc
2,020 employeesPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...